26 May 06
Although ventricular and atrial fibrillation represent the most common cardiac arrhymias and are associated with amongst the highest rates of cardiovascular morbidity and mortality, treatment options are suboptimal. New opportunities are however approaching the market, notably Cardiome’s RSD1235, paving the way for development by others.
24 May 06
DailyUpdates 24th May, 2006: With the threat of influenza hanging over our heads on a seemingly continuous basis, improving the ability to rapidly and accurately identify patients infected with influenza and furthermore the strain of virus remains paramount. Today we feature research from CombiMatrix concerning their activities in this area. We also headline news coming out of Denmark's Genmab announcing the advance of HuMax-CD20, the company's CD20 monoclonal, into the clinic for the treatment
22 May 06
ExL Pharma is proud to present the inaugural Pharmaceutical Advocacy & Lobbying Forum, the leading event for government and public affairs professionals to address best practices to obtain optimal outcomes on key federal and state legislative issues impacting your company. According to in-depth research and feedback from industry executives, this event is a much needed resource for industry colleagues to meet, learn and network on lobbying and advocacy tactics to ensure the delivery of innovativ
22 May 06
DailyUpdates 18th May, 2006: As the antidepressant sector continues to go through a period of turbulance we report on new data for one blockbuster from this class - Lexapro. Selected for special mention from over 50 journal articles today's feature demonstrates great timing appearing at the same time as our feature - Major Depressive Disorder. Today's edition of DailyUpdates can be seen here
19 May 06
DailyUpdates 19th May, 2006: Today's edition of DailyUpdates (see it in full here) carries a couple of important articles on renal disease. One loks at the outcome of patients with renal dysfunction across various acute coronary syndromes. The featured article however demonstrates the efficacy of Novartis' Benazepril in treating advanced renal disease
17 May 06
Despite almost 200 million people suffering from hypertension in the seven major pharmaceutical markets alone, according to a new report, innovation is scarce within antihypertensive R&D. What little innovation that does exist is being delivered by Novartis, which is set to launch two new antihypertensives in 2007 in the shape of oral renin inhibitor Rasilez, and the 'two-in-one' pill Exforge.
17 May 06
EntreMed has initiated a phase II trial of Panzem in combination with Genentech's Avastin in carcinoid cancer. The trial will examine how the therapy fares against potential rivals and its possible use in other tumor types. With the blockbuster Avastin possessing the potential to significantly raise the profile of Panzem, the study will prove crucial for EntreMed's lead pipeline drug candidate.
15 May 06
DailyUpdates 15th May, 2006: Amongst the 50 or so papers and press releases featured today two focusing on VEGF jump out as being of especial interest. The first, a paper published by Stanford University, reports on the anti-cancer activity of an oncolytic virus in combination with gene therapy. The virus was engineered to selectively replicate in and kill cancer cells . The gene therapy encoded a soluble version of Flk1, one of the VEGF receptors. The two approaches together produce effective a
15 May 06
When not doing 'insane sports', Amgen's Europe chief Rolf Hoffmann is battling big pharma
13 May 06
This summit aims to provide both strategic and practical information that will ensure that organisations can prepare for and survive what is now considered to be the inevitable pandemic. Professor Hugh Pennington from the Department of Medical Microbiology at University of Aberdeen will repeat his warning that, “Only one thing is certain and that is that there will be a pandemic.”
12 May 06
DailyUpdates 12th May, 2006 (click here for entire bulletin): Today appears to be cancer vaccine day with two important announements being made. First off, Genitope Corporation announce the initiation of an ealry phase clinical trial of their MyVax idiotype immunotherapy; this was followed by an announcement by Biovest reporting that fast track status had been awarded to their phase 3 candidate, BiovaxID. This follows in the footsteps of the company's announcement that the FDA had approved sale
11 May 06
A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.
10 May 06
This Conference will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general. Opportunities and challenges within the whole value chain, from research and development down to sales and marketing will be discussed and solutions put forward for the benefits of attendees.
IBG Company Limited
25 Apr 06
Specialty Pharma transformations and venture investments have continued to grow at an unprecedented pace. The 2006 meeting is an elite opportunity for Big Pharma, Biotech, and Drug Delivery to network with the industry's fastest growing Specialty Pharma companies and discover what makes them so attractive as a partner.
07 Apr 06
COPD is a disease that will grow in importance in the future and it will have a major impact on society, particular amongst those that smoke. At the moment, although new treatments are being developed for COPD the pharmaceutical market remains undeveloped. There will be a high demand for effective medicines and so COPD should be an area of interest for pharmaceutical companies who specialise in the respiratory therapeutic field.
Dr Faiz Kermani
07 Apr 06
Healthcare is receiving greater attention in Latin America than ever before and a number of countries in the region are in the midst of major reforms. The government policies that are being developed have important implications for pharmaceutical companies looking to expand in this emerging pharmaceutical region.
Dr Faiz Kermani
06 Apr 06
SMi’s Clinical Trials in Cancer conference will provide up-to-date information on the current challenges in clinical development, with an insight into European and US regulatory requirements. Attendees will benefit from presentations on key novel therapies currently in development and how they are being integrated into clinical trials.
Don't miss this opportunity to meet experts in the field as they discuss how anti-cancer drug development can be optimised and carried forward to achieve the u
03 Apr 06
Corning Life Sciences today announced the addition of digital displays and enhanced features to its hot plates, stirrers and stirring hot plates. The new digital display features include: a digital temperature display adjustable in 5 degree increments and set temperature indicator; optimum digital stir speed display indicator; and an external temperature controller for precision accuracy “inside the beaker.”
Corning Life Sciences
03 Apr 06
Corning Life Sciences today announced several new products coated with the Ultra-Low Attachment surface including the 25 and 75 cm2 flasks and CELLSTACK® Culture Chambers which are well-suited for many cell culture applications including stem cell, cancer, and immune system research, and enable customers to increase the scale of cell culture, improve yields, and reduce contamination risks
Corning Life Sciences
30 Mar 06
Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
29 Mar 06
Deployable medicine involves the complete employment of military health professionals. The nature of the deployment can vary from conventional ‘warfighting’ campaigns to humanitarian relief operations. The methods for employing highly skilled military professionals within the area or operations and the level of care they provide are crucial to the success of the mission
29 Mar 06
The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's atorvastatin/torcetrapib. Studies demonstrating that higher doses of existing products can offer improved efficacy but with no increase in side-effects will also help optimize sales in the antidyslipid
28 Mar 06
Heart failure affects more than 5 million people in the U.S. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care system cost of $15 billion. Given the paucity of the pipeline for acute congestive heart failure, the best hope of clinical improvement will involve improved utilization of existing therapies. However early intervention requires rapid and accurate diagnosis. Given its diagnostic potential, the measurement of plasma BNP a
22 Mar 06
According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004. The pain market can be divided into acute pain which is well served by OTC medications, post-operative pain and chronic pain. One of the most challenging areas of analgesia is the treatment of chronic neuropathic pain. Cancer pain also represents a largely unmet market which along with post-operative analgesia depends to a large extent on opioid-based th
21 Mar 06
If Sales Force Effectiveness is high on your agenda in the current climate, then don’t miss Pharma IQ’s Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.